Pediatric ADPKD mGFR and eGFR Comparison

Overview

About this study

The purpose of this study is to compare measured glomerular filtration rate (mGFR) using Iothalamate, a gold standard marker, with various creatinine (Cr)-based and cystatin (Cys)-based estimated GFR (eGFR) calculations in pediatric patients with autosomal dominant polycystic kidney disease (ADPKD). Also, to determine the level of agreement between mGFR and different eGFR equations in pediatric patients with ADPKD.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Any ADPKD patient (ages 9-18 years) with confirmed ADPKD (via a combination of imaging, family history, and/or genetic testing), identified from existing and newly identified families for the proposed study.

Exclusion Criteria: 

  • ADPKD patients with liver and or kidney transplant.
  • Patients with contraindications to the administration of Iothalamate will be excluded from participating in the study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/1/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Christian Hanna, M.D., M.S.

Open for enrollment

Contact information:

Ryan Helland

(507) 422-3998

Helland.Ryan@mayo.edu

More information

Publications

Publications are currently not available